Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An evaluation of the safety and performance of the STANZA Drug-eluting Resorbable Scaffold (DRS) system for the treatment of patients with obstructive superficial femoral artery disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Drug Eluting Peripheral Vascular Stent System in Superficial Femoral Artery Stenosis and /or Occlusion

NCT03121430

Peripheral Arterial Disease Superficial Femoral Artery Stenosis Superficial Femoral Artery Occlusion

UNKNOWN NA

Tolerance Study of Allogeneic of Adipose Tissue Derived Mesenchymal Stroma/Stem Cells (AdMSC) Transplantation in Patients With Critical Limb Ischemia.

NCT06795620

Critical Limb Ischemia

NOT_YET_RECRUITING PHASE1

Phase II Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia

NCT00721006

Critical Limb Ischemia Severe Leg Ischemia Peripheral Artery Disease +1 more

COMPLETED PHASE2

Evaluate the Efficacy and Safety of the Cilostazol-coated BioMimics 3D Stent System in Patients with Peripheral Arterial Occlusive Disease

NCT05759819

Peripheral Arterial Disease

ACTIVE_NOT_RECRUITING NA

Feasibility of Peripheral Angioplasty in Type D TASCII Lesions

NCT01297387

Diabetes Critical Limb Ischemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The STANZA DRS system is comprised of a controlled release paclitaxel-eluting bioresorbable scaffold and a delivery system used in the treatment of superficial femoral artery disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease Intermittent Claudication Vascular Diseases Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

STANZA Drug-eluting Resorbable Scaffold

Treatment of Superficial Femoral Artery (SFA) lesion with resorbable scaffold

Group Type EXPERIMENTAL

STANZA Drug-eluting resorbable Scaffold

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

STANZA Drug-eluting resorbable Scaffold

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Paclitaxel-eluting resorbable scaffold

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \> 18 years.
2. De novo stenotic lesion(s) in the superficial femoral artery located at least 1 cm distal to the femoral bifurcation and \> 5 cm above the joint space of the knee.
3. Patient has symptomatic intermittent claudication affecting at least the target leg (Rutherford Class 2-3). Patients should have first received conservative medical management of their symptoms prior to study inclusion. The symptoms can be bilateral.
4. The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the ethics committee of the respective clinical site.
5. The study patient agrees to comply with all required post-procedure study requirements.

1. Reference vessel diameter (RVD) 5.0 -6.0 mm measured by an objective measurement such as online Quantitative Vessel Analysis (QVA).
2. Target lesion length ≤ 90 mm; total occlusion length \< 40 mm.
3. Target lesion has a ≥70% diameter stenosis.
4. Angiographic evidence of at least one runoff vessel to the ankle/foot without hemodynamically significant stenosis (\>50% diameter stenosis) that does not require any treatment within 3 months of the index procedure.
5. Procedural access can be accomplished via contralateral vascular access or if antegrade access no closure device can be utilized and closure has to occur via manual pressure.
6. Patent common and external iliac: TASC A \& B iliac lesions may be treated at the time of index procedure (before treatment of the target lesion) if residual stenosis is ≤30%.

Exclusion Criteria

1. Previous vascular surgery/endovascular treatment of the target lesion.
2. Re-vascularization of target vessel within 30 days of study procedure.
3. Critical limb ischemia defined as Rutherford Becker Category 4-6.
4. Known coagulation disorders or intolerance or allergies to aspirin, clopidogrel or ticlopidine, heparin, any scaffold components, contrast agents which cannot be adequately pre-medicated.
5. Life expectancy ≤12 months.
6. Planned procedure that necessitates the discontinuation of antiplatelet medications used in conjunction with the investigational device within 3 months post-procedure.
7. Inability to walk due to orthopedic or other nonvascular complications.
8. Pregnancy or breast feeding or patient desires to become pregnant.
9. Non-atherosclerotic lesion (e.g. vasculitis).
10. Renal insufficiency (serum creatinine level \> 220 µmol/L or \> 2.5 mg/dl, or patient is on dialysis).
11. Patient has medical condition(s) which could affect study assessments or may adversely affect the safety and/or success of the study treatment.
12. Active systemic infection or lower limb infection of any nature.
13. White Blood Cells (WBC) ≤ 3,000 cells/mm3.
14. Myocardial infarction within 30 days prior to the study procedure.
15. Stroke within 90 days prior to the study procedure.
16. Uncontrolled atrial fibrillation.
17. Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
18. Prior use of paclitaxel-eluting products in the target limb less than 6 months prior to index procedure.
19. Patient has known unstable angina.

1. Target lesion treatment with a drug eluting balloon.
2. Target lesion treatment with atherectomy, laser, or cryoplasty (use of a cutting or scoring balloon is permitted prior to scaffold implantation only).
3. Suspicion for or evidence of subintimal passage of guidewire.
4. Severely calcified lesion(s).
5. Target lesion which, based on two angiographic orthogonal views, exhibit a persistent balloon deformity during pre-dilatation with a nominally sized balloon.
6. Target vessel (superficial femoral artery) has an angiographically significant (\> 50% diameter stenosis) lesion located distally or proximally to the target lesion.
7. Acute embolic complication following pre-dilatation.
8. Target vessel contains an acute thrombus.
9. Aneurysm in target vessel or co-existing clinically significant aneurysmal disease of the abdominal aorta, iliac or popliteal arteries.
10. Intervention in the infra-inguinal arteries outside of the target lesion.
11. Planned procedure within 30 days after the index procedure.
12. Positive pregnancy test for females of child bearing potential.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes